13 January 2021
Arvelle Therapeutics acquired by Angelini Pharma
By Lindsey Neville
Consilium started working with Mark Altmeyer, President & CEO, Greg Weinhoff, CBO & CFO and the wider team at Arvelle Therapeutics in October 2019 with the primary goal of raising the profile of Arvelle internationally in front of all financial, medical and business development stakeholders. Arvelle, based in Zug, Switzerland is a biopharmaceutical company responsible for the development and commercialisation of cenobamate, an investigational antiepileptic drug, in the European market following a licensing deal secured with SK Biopharmaceuticals in South Korea.
By implementing a comprehensive strategic communications programme, Consilium helped to position Arvelle as a flagship company as it made the transition from a clinical to commercial stage business with plans to launch cenobamate in Europe.
Working collaboratively with the Arvelle team, Consilium positioned the corporate story explaining the product and the underlying science, highlighting the experienced management team and Board, the international blue-chip investor base, the company’s commercial strategy and the size of the market opportunity. Another key aspect of our work was building and strengthening relationships between the management team and sell-side analysts, investors, and key international media.
The culmination of Consilium’s work with Arvelle was its acquisition by Angelini Pharma, an international pharmaceutical company, for a total aggregate valuation of up to $960 million in January 2021.
The Consilium team advising Arvelle was Mary-Jane Elliott, Susan Stuart, Alex Harrison, Lindsey Neville, Carina Jurs and Kris Lam.